Provided by Tiger Trade Technology Pte. Ltd.

Global Partners LP

50.50
+0.10000.20%
Volume:45.00K
Turnover:2.27M
Market Cap:1.72B
PE:10.33
High:50.79
Open:50.42
Low:49.90
Close:50.40
52wk High:53.24
52wk Low:39.58
Shares:34.00M
Float Shares:27.67M
Volume Ratio:0.91
T/O Rate:0.16%
Dividend:3.06
Dividend Rate:6.05%
EPS(TTM):4.89
EPS(LYR):2.11
ROE:27.21%
ROA:5.25%
PB:2.56
PE(LYR):23.93

Loading ...

GLP-1 boom nudges U.S. cannabis dispensaries to rethink offerings

Bloomberg
·
Apr 21

LifeMD Shares Rise After Offering Lilly's GLP-1 Obesity Pill

Dow Jones
·
Apr 21

ResMed: Buy Rating on Depressed Valuation as Market Overprices Philips and GLP‑1 Risks

TIPRANKS
·
Apr 17

ASCLETIS-B Shares Surge Nearly 5% in Afternoon Trading, Approaching All-Time High as GLP-1 and Amylin Combo Enters Clinical Trials

Stock News
·
Apr 17

TYK MEDICINES-B's (02410) Self-Developed TY-3002 Monotherapy Demonstrates Outstanding Weight Loss Efficacy, Pioneering Next-Generation Oral GLP-1R Small Molecule Innovation

Stock News
·
Apr 16

Lexaria Launches New GLP-1 Study to Expand Drug Delivery IP

TIPRANKS
·
Apr 15

Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study

TIPRANKS
·
Apr 15

Study flags unreported GLP-1 side effects in analysis of social media posts

Bloomberg
·
Apr 14

Strategic Merger in CRO Sector: Baijun Biotech and Hugang Zhongke Sign Integration Agreement

Deep News
·
Apr 14

Morgan Stanley Sticks to Their Buy Rating for GLP J-REIT (3281)

TIPRANKS
·
Apr 14

Press Release: Global Partners Announces Cash Distribution on Series B Preferred Units

Dow Jones
·
Apr 13

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences

GlobeNewswire
·
Apr 13

GLP J-REIT Posts Lower Profit After Asset Sales but Keeps Payouts Steady

TIPRANKS
·
Apr 13

GLP J-REIT Outlines Fiscal 2026 Outlook and Growth Strategy

TIPRANKS
·
Apr 13

GLP-1 Genetics Could Inform Treatment, Supporting Future Precision Medicine Approaches

Deep News
·
Apr 09

Vanda Pharmaceuticals: Undervalued GLP-1 Adjunct Opportunity Driven by Tradipitant’s Pivotal Thetis Trial

TIPRANKS
·
Apr 09

We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play. -- Barrons.com

Dow Jones
·
Apr 09

Oral GLP-1 Medications Expand Obesity Treatment Market, Attracting Patients Averse to Injections

Deep News
·
Apr 07

ASCLETIS-B Advances Clinical Development of Fixed-Dose Combination ASC30_39 for Obesity Treatment

Stock News
·
Apr 07

PegBio's CR059 Selection for ADA Late-Breaking Abstract Highlights Monthly-Dosing GLP-1 Potential

Stock News
·
Apr 07